Overview

A Study to Evaluate the Efficacy and Safety of Mizoribine in the Treatment of Lupus Nephritis

Status:
Completed
Trial end date:
2019-03-01
Target enrollment:
Participant gender:
Summary
To demonstrate that the treatment effect in lupus nephritis of MZR is non-inferior to that of standard therapy CTX through analyzing overall remission rate after treatment.
Phase:
Phase 3
Details
Lead Sponsor:
Asahi Kasei Pharma Corporation
Treatments:
Bredinin
Cyclophosphamide
Mizoribine